← Back to patent-cliff list
ILB-2109
Tier C — Watch / tradeILB-2109
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：ADORA2A
Indications (approved)：Solid tumour, Nasopharyngeal carcinoma, Non-small cell lung cancer, Cervical cancer, Melanoma, Hodgkin's disease, Ovarian cancer, Sarcoma
Regional status
US
-
2022-01-01
EU
-
China
Phase II
2023-07-25
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ILB-2109?
Approved indications include: Solid tumour, Nasopharyngeal carcinoma, Non-small cell lung cancer, Cervical cancer, Melanoma, Hodgkin's disease, Ovarian cancer, Sarcoma.
When does the ILB-2109 patent expire?
No public expiry year is available for ILB-2109 yet; this page updates once verified.
How do I get a quote for ILB-2109 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02